# Sarkome

> Sarkome is a single-asset entity (SAE) dedicated to identifying, validating, and licensing a selective protein degrader (SAR-001) for Alveolar Soft Part Sarcoma (ASPS).

## Core Documentation

- [Home](index.md): Overview of the ASPS Therapeutics Discovery Initiative, mission, and key scientific facts.
- [About](about.md): The story and mission behind Sarkome.

## Research & Science

- [ASPS Overview](asps.md): Detailed information on Alveolar Soft Part Sarcoma and the ASPSCR1-TFE3 fusion driver.
- [The Gap](the_gap.md): Analysis of the "Epistemological Gap" in current discovery methods and the need for new approaches.
- [Discovery Engine](discovery_engine.md): The virtual-first drug discovery platform using agentic AI and cloud labs.
- [Roadmap](roadmap.md): Strategic development plan from in silico design to clinical proof of concept.

## Optional

- [Home Page](/): The main website landing page.
- [About Page](/about): The website about page.
